|
?:authorAffiliation
|
-
[\'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Electronic address: maheshi.ramasamy@paediatrics.ox.ac.uk.\', \'The Jenner Institute, University of Oxford, Oxford, UK.\', \'NIHR Clinical Research Facility, University Hospital Southampton NHS Trust, Southampton, UK.\', \'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.\', \'Paediatric Medicine, University of Southampton, Southampton, UK.\', \'National Infection Service, Public Health England, Porton Down, Salisbury, UK.\', \'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.\', \'Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK.\', \'AstraZeneca BioPharmaceuticals Research and Development, Washington, DC, USA.\', \'Nuffield Department of Medicine, and Oxford Centre for Clinical Tropical Medicine and Global Health, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.\', \'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Division of Infectious Diseases, Boston Children\'s Hospital, Boston, MA, USA.\', \'AstraZeneca BioPharmaceuticals Research and Development, Bethesda, MA, USA.\', \'The Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.\', \'NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Trust and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}